Skip to main content

Advertisement

Log in

Mediastinal mass mimicking a tumor in a patient with bladder cancer after bacillus Calmette-Guerin treatment

  • Case Report
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

We describe the case of a 78-year-old male with bladder cancer who developed a mediastinal mass after intravesical immunotherapy with live Mycobacterium bovis BCG. The clinical diagnosis was mediastinal tumor suggestive for lymphoma. However, cultures of the biopsy specimens grew an acid-fast organism, which was identified as M. bovis BCG. To the best of our knowledge, this is the first reported case in which a postinstillation BCG infection induced a mediastinal mass that mimicked a tumor in a patient with bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Grange JM, Gibson J, Osborn TW, Collins CH, Yates MD (1983) What is BCG? Tubercle 64:129–139

    Article  PubMed  CAS  Google Scholar 

  2. Davis JW, Sheth SI, Doviak MJ, Schellhammer PF (2002) Superficial bladder carcinoma treated with bacillus Calmette-Guerin: progression-free and disease specific survival with minimum 10-year followup. J Urol 167:494–500

    Article  PubMed  Google Scholar 

  3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30

    Article  PubMed  Google Scholar 

  4. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, Rodriguez RH, Gomez JM, Martin MG, Molina JR, Collado AG, Flores N, Isorna S, Pertusa C, Rabadan M, Astobieta A, Camacho JE, Arribas S, Madero R (2005) Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 174:1242–1247

    Article  PubMed  Google Scholar 

  5. de Boer EC, Rooyakkers SJ, Schamhart DH, de Reijke TM, Kurth KH (2005) BCG dose reduction by decreasing the instillation frequency: effects on local Th1/Th2 cytokine responses in a mouse model. Eur Urol 48:333–338

    Article  PubMed  CAS  Google Scholar 

  6. Mungan NA, Witjes JA (1998) Bacille Calmette-Guerin in superficial transitional cell carcinoma. Br J Urol 82:213–223

    PubMed  CAS  Google Scholar 

  7. Paterson DL, Patel A (1998) Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: review of complications and their treatment. Aust NZ J Surg 68:340–344

    CAS  Google Scholar 

  8. Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW, Soloway MS, Steg A, Debruyne FM (1992) Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 147:596–600

    PubMed  CAS  Google Scholar 

  9. Rischmann P, Desgrandchamps F, Malavaud B, Chopin DK (2000) BCG intravesical instillations: recommendations for side-effects management. Eur Urol 37(suppl 1):33–36

    Article  PubMed  Google Scholar 

  10. Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG (1986) Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 135:272–274

    PubMed  CAS  Google Scholar 

  11. Hunt JS, Silverstein MJ, Sparks FC, Haskell CM, Pilch YH, Morton DL (1973) Granulomatous hepatitis: a complication of B.C.G. immunotherapy. Lancet 2:820–821

    Article  PubMed  CAS  Google Scholar 

  12. Bodurtha A, Kim YH, Laucius JF, Donato RA, Mastrangelo MJ (1974) Hepatic granulomas and other hepatic lesions associated with BCG immunotherapy for cancer. Am J Clin Pathol 61:747–752

    PubMed  CAS  Google Scholar 

  13. Kristjansson M, Green P, Manning HL, Slutsky AM, Brecher SM, von Reyn CF, Arbeit RD, Maslow JN (1993) Molecular confirmation of bacillus Calmette-Guerin as the cause of pulmonary infection following urinary tract instillation. Clin Infect Dis 17:228–230

    PubMed  CAS  Google Scholar 

  14. Tuncer S, Tekin MI, Ozen H, Bilen C, Unal S, Remzi D (1997) Detection of bacillus Calmette-Guerin in the blood by the polymerase chain reaction method of treated bladder cancer patients. J Urol 158:2109–2112

    Article  PubMed  CAS  Google Scholar 

  15. Witebsky FG, Keiser JF, Conville PS, Bryan R, Park CH, Walker R, Siddiqi SH (1988) Comparison of BACTEC 13A medium and DuPont isolator for detection of mycobacteremia. J Clin Microbiol 26:1501–1505

    PubMed  CAS  Google Scholar 

  16. Gonzalez OY, Musher DM, Brar I, Furgeson S, Boktour MR, Septimus EJ, Hamill RJ, Graviss EA (2003) Spectrum of bacille Calmette-Guerin (BCG) infection after intravesical BCG immunotherapy. Clin Infect Dis 36:140–148

    Article  PubMed  Google Scholar 

  17. Bedwell J, Kairo SK, Behr MA, Bygraves JA (2001) Identification of substrains of BCG vaccine using multiplex PCR. Vaccine 19:2146–2151

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgement

The authors wish to thank Susan Dean for her assistance in data collection and Dr. David Ashkin for his critical review of the manuscript.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Salfinger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Somoskovi, A., Carlyn, C., Dormandy, J. et al. Mediastinal mass mimicking a tumor in a patient with bladder cancer after bacillus Calmette-Guerin treatment. Eur J Clin Microbiol Infect Dis 26, 937–940 (2007). https://doi.org/10.1007/s10096-007-0390-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-007-0390-5

Keywords

Navigation